Detection of Antisperm Antibody in Vasectomized and Infertile Males / 대한비뇨기과학회지

We studied antisperm antibody by the use of the tray agglutination test in sera of 37 vasectomized males and 65 infertile males Antisperm antibody was found in 27 out of 37 vasectomized males (73%). Antibody titer was more than 1:32 in majority of the patients (25/27). The most common agglutination pattern was tail-to-tail agglutination (70.5 %). Antisperm antibody was found in 7 out of 17 obstructive azoospermia (41.2 %), and 3 out of 42 idiopathic infertility (7.1 %). But none was found in 6 patients with varicocele.

A Blind-Ending Bifid Ureter with Stones / 대한비뇨기과학회지

Blind-ending bifid ureter represents a rare anomaly in the development of the ureteric bud, and a case associated with stone formation is extremely rare. We report a case of blind-ending bifid ureter with stones in the blind segment with a brief review of literature.

Endoscopic Internal Urethrotomy in the Management of urethral Stricture / 대한비뇨기과학회지

27 endoscopic internal urethrotomy was done on 24 patients with urethral strictures. the results were as follows: 1. Endoscopic internal urethrotomy can be performed under local anesthesia. 2. It can be repeated if necessary. 3. other endoscopic procedures were done simultaneously on 5 cases. 4. Complications were minimal, one case of epididymitis and one of sepsis. 5. When carefully performed this procedure is highly useful for the primary management of any urethral stricture.

Congenital Agenesis of the Vas Deferens / 대한비뇨기과학회지

Thirty three patients with congenital agenesis of the vas deferens were investigated in Seoul National University Hospital for the past 10 years. These patients correspond to 2.4% of 1,398 infertile males and 14.8% of 223 azoospermic patients due to epididymal obstruction. These anomalies were confirmed by surgical explorations, They were consisted of 24 patients with bilateral agenesis of the vas deferens and 9 patients with unilateral agenesis(5 in right side, 4 in left side). Type 2 anomaly, vas agenesis without defects of epididymis, was found in 25(44%) of a total of 57 anomalies of the vas deferens. Type 1 anomaly, vas agenesis with defects on body or tail of epididymis, was found in 21(37%), and type 3 in which the head of epididymis and distal vas are identified but body and tail of epididymis and proximal vas are absent, was found in 11(19%). The histological examination of the testis showed normal spermatogenesis in the most of the patients, The seminal volume was reduced in 24 patients, and normal in 9 patients. The seminal fructose was reduced in 13 patients. It is suggested that vas agenesis would be associated with the absence of seminal vesicle in patients with reduced seminal volume and reduced seminal fructose level. In seven patients with unilateral agenesis of the vas deferens, the obstructive lesions of epididymal tails of contralateral side were corrected by epididymovasostomy under surgical microscope. The results were successful in 2 patients. In three patients with bilateral agenesis of the vas deferens of type 3, epididymovasostomy could be performed. Successful results were obtained in 2 patients. In conclusion, the results of this clinical investigation emphasize the importance of careful scrotal examination in the diagnosis of an infertile males and in the preparative examination of vasectomy operation.

Male Infertility: XII. Pharmacological Treatment for Improving Semen Motility / 대한비뇨기과학회지

Some investigators suggest that the pancreatic proteinase kallikrein plays an important role in the regulation of spermatozoal motility. Particularly, oral kallikrein therapy exerted a favorable effect on Sperm motility in oligozoospermia and asthenozoospermia. We have carried out a similar clinical investigation of the efficacy of kallikrein, taken orally 60 kU per day for 3-9 months, on the quantitative and qualitative motility of spermatozoa in normogonadotropic infertile men. with 15 idiopathic oligozoospermia and 18 idiopathic asthenozoospermia. Number of spermatozoa increased more than double number of basic levels (over 40 x 10(6)/ml) in the 5 patients (33%) and pregnancy occurred in the 3 patients (20%) out of the 15 patients with idiopathic oligozoospermia (less than 20 x 10(6)/ml) after the kallikrein therapy. In these responded 5 patients, the sperm concentration changed from 13.6 x 10(6)/ml to 54.0 x 10(6)/ml, Motility and viability of spermatozoa improved more than 30% in the 5 patients (28%) and pregnancy occurred in the 2patients (11%) out of the 18 patients with idiopathic asthenozoospermia (less than 20% of sperm motility) after the therapy. In these. improved 5 patients, the sperm motility changed from 9.0% to 45.0%. No remarkable side effect was detected.

Male Infertility: XII. Pharmacological Treatment for Improving Semen Motility / 대한비뇨기과학회지

Some investigators suggest that the pancreatic proteinase kallikrein plays an important role in the regulation of spermatozoal motility. Particularly, oral kallikrein therapy exerted a favorable effect on Sperm motility in oligozoospermia and asthenozoospermia. We have carried out a similar clinical investigation of the efficacy of kallikrein, taken orally 60 kU per day for 3-9 months, on the quantitative and qualitative motility of spermatozoa in normogonadotropic infertile men. with 15 idiopathic oligozoospermia and 18 idiopathic asthenozoospermia. Number of spermatozoa increased more than double number of basic levels (over 40 x 10(6)/ml) in the 5 patients (33%) and pregnancy occurred in the 3 patients (20%) out of the 15 patients with idiopathic oligozoospermia (less than 20 x 10(6)/ml) after the kallikrein therapy. In these responded 5 patients, the sperm concentration changed from 13.6 x 10(6)/ml to 54.0 x 10(6)/ml, Motility and viability of spermatozoa improved more than 30% in the 5 patients (28%) and pregnancy occurred in the 2patients (11%) out of the 18 patients with idiopathic asthenozoospermia (less than 20% of sperm motility) after the therapy. In these. improved 5 patients, the sperm motility changed from 9.0% to 45.0%. No remarkable side effect was detected.